Predicting the efficacy of anthracyclines in breast cancer (BC) patients: The results of the TOP trial

ABSTRACT: PURPOSE: Validated biomarkers predictive of response/resistance to anthracyclines in breast cancer are currently lacking. The neoadjuvant TOP trial, in which patients with estrogen receptor (ER)-negative tumors were treated with anthracycline (epirubicin) monotherapy, was specifically designed to evaluate the predictive value of topoisomerase IIα (TOP2A) and to develop a gene expression signature to identify those patients who do not benefit from anthracyclines. METHODS: The TOP trial included 149 patients, of which 141 were evaluable for response prediction analyses. The primary endpoint was pathological complete response (pCR). TOP2A and gene expression profiles were evaluated using pre-epirubicin biopsies. Gene expression data from ER-negative samples of the EORTC 10994/BIG 00-01 and

ORGANISM(S): Homo sapiens

SUBMITTER: Desmedt C 

PROVIDER: S-ECPF-GEOD-16446 | biostudies-other | 2010 Apr

REPOSITORIES: biostudies-other